Randomised, Phase III Multicenter, Open Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Presenting Elevated Chromogranin A Levels.
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2015
At a glance
- Drugs Lanreotide (Primary) ; Bicalutamide; Triptorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms POSEIDON
- Sponsors Ipsen
- 10 Jun 2017 Biomarkers information updated
- 31 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Oct 2012 Planned end date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.